Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + docetaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib + docetaxel is a combination therapy used primarily in the treatment of advanced non-small cell lung cancer (NSCLC), particularly in patients with wild-type EGFR, and has also been studied for metastatic gastric cancer. Apatinib is an oral small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis and tumor blood supply. Docetaxel is a cytotoxic chemotherapeutic agent belonging to the taxane class, which stabilizes microtubules and inhibits cell division. The combination has shown efficacy in delaying disease progression and improving survival outcomes in heavily pretreated or refractory cases of NSCLC, including those with brain metastases, as well as being investigated for use in metastatic gastric cancer. The regimen generally demonstrates a tolerable safety profile[1][2][3][5].
- Brand names
- None
- Other names
- None
02
Targets
TUBB (Tubulin (alpha and beta subunits))ABCG2 (Breast cancer resistance protein)ABCB1 (P-glycoprotein)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on apatinib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + docetaxel.